Plain-English translation of NCT06111625 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a targeted cancer medication, can safely prepare patients with a type of blood cancer called B-cell acute lymphoblastic leukemia for a stem cell transplant. The medication is given through an IV for 5 to 10 days before the transplant procedure. Researchers want to know if this approach helps improve outcomes and is well-tolerated by patients.
Patients with low amounts of remaining leukemia cells before transplant may benefit from an extra treatment to reduce cancer burden further and improve their chances of long-term survival. This trial is exploring whether this medication can safely bridge the time between diagnosis and transplant.
You likely qualify if…
You likely don't qualify if…
You will receive the medication through an IV over 5 to 10 days, with the dose gradually increasing to help your body tolerate it well. You will also receive a steroid medication to help prevent side effects. After completing the medication course, you will undergo conditioning chemotherapy followed by a stem cell transplant from a matched donor. You will then have follow-up visits at regular intervals (1, 2, 3, 4, 6, 9, 12, 18, and 24 months after transplant) to monitor your recovery and health.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China